Please select the option that best describes you:
In patients with Philadelphia-negative ALL who are transplant ineligible, is there any data to guide duration of maintenance POMP therapy?
Does your approach change if MRD negative post-blinatumomab?
Does your approach change if MRD negative post-blinatumomab?